About this trial
Vitiligo is the most common depigmentation disorder affecting around 1% of the population worldwide. Fifty two percent of patients develop vitiligo before the age of 20 and around 80% develop vitiligo before the age of 30 years old.1 Vitiligo often presents in childhood and tends to be a lifelong disease, requiring prolonged courses of phototherapy.
Currently no national or international registry for patients with vitiligo exists. Individual dermatologists maintain a database of such patients, however no coordinated efforts have been made to combine these individual registries into a broader national registry. Finally, recently published British Association of Dermatologists (BAD) guideline for the management of vitiligo, recommended the development of a national registry for people with vitiligo undergoing systemic or light therapy to identify outcomes and safety.
Eligibility criteria
Qualifiers
Paediatric and adult patients with vitiligo under management in secondary care.
Written informed consent for study participation obtained from the patient or parents / legal guardian, with assent as appropriate by the patient, depending on the level of understanding.
Participants consent to participate in long-term follow up and access to all relevant medical records as needed by the study team
Clinical diagnosis of vitiligo made by a dermatologist
Disqualifiers
Insufficient understanding of the study by the patient and/or parent/guardian.
Patients with vitiligo/their parents or guardians, who do not provide consent for participation.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
The Royal Wolverhampton Hospitals NHS Trust
Lead sponsor
Incyte Biosciences International Sàrl
Collaborator